灭活SARS-CoV-2疫苗不增加临床非活动性成人起病Still病患者复发风险
前瞻性纳入122例临床非活动性成人起病Still病(AOSD)患者,其中49.2%(n=60)自愿接种灭活SARS-CoV-2疫苗(BBIBP-CorV,国药集团,中国北京)。经倾向性评分匹配(PSM)后,接种组与未接种组复发率均为6.8%,接种后1个月内无复发,75.0%的参与者未报告明显不良反应,无严重反应。结论认为接种后疾病活动增加或复发罕见,局部和全身不良反应轻微且自限。
要点
- 临床非活动性AOSD患者接种灭活SARS-CoV-2疫苗后复发率未显著增加(PSM后6.8% vs 6.8%)。
- 接种后1个月内无复发,75.0%的参与者无明确不良反应,无严重反应报告。
- 局部和全身不良反应轻微且自限,疫苗安全性特征可能有助于消除疫苗犹豫。
核心结论
- 在临床非活动性AOSD患者中,接种灭活SARS-CoV-2疫苗后疾病活动增加或复发罕见,局部和全身不良反应轻微且自限。
研究设计与样本
- 前瞻性纳入就诊于本科室门诊的临床非活动性AOSD患者,患者自愿接种灭活SARS-CoV-2疫苗(BBIBP-CorV,国药集团,中国北京),随访期间记录复发情况,并采用倾向性评分匹配(PSM)比较接种组与未接种组的复发率。
主要发现
- 共纳入122例非活动性AOSD患者,49.2%(n=60)自愿接种了灭活SARS-CoV-2疫苗。
- 经PSM后,接种组与未接种组复发率均为6.8%(6.8% vs 6.8%),接种组复发率未显著增加。
- 接种后1个月内未发生复发。
- 75.0%的参与者未报告明显不良反应,无患者报告严重反应。
关键数值与推荐
- PSM后接种组复发率6.8% vs 未接种组6.8%。
- 49.2%(n=60)的纳入患者接种了灭活SARS-CoV-2疫苗。
- 75.0%的参与者未报告明显不良反应,无严重反应报告。
临床怎么用
- 原文结论指出,灭活SARS-CoV-2疫苗在AOSD患者中的安全性特征可能有助于消除疫苗犹豫并提高SARS-CoV-2疫苗接种率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A succession of cases have reported flares of adult-onset Still's disease (AOSD) after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raising concerns. We aimed to investigate the impact of inactivated SARS-CoV-2 vaccines on disease activity in patients with AOSD. METHODS: We prospectively enrolled clinically inactive AOSD patients visiting the outpatient clinics of our department. The patients received SARS-CoV-2 vaccines (BBIBP-CorV, Sinopharm, Beijing, China) voluntarily. The occurrence of relapse in the participants was recorded during the follow-up period, and a propensity score matching (PSM) method was used to compare the relapse rates between vaccinated and unvaccinated patients. Localized and systemic symptoms were assessed in the vaccinated patients. RESULTS: A total of 122 patients with inactive AOSD were included, of which 49.2% (n = 60) voluntarily received the inactivated SARS-CoV-2 vaccine. The relapse rate did not increase significantly in vaccinated patients in comparison with unvaccinated patients (after PSM: 6.8% vs 6.8%), and no relapse occurred within 1 month after vaccination. No obvious adverse reactions were reported in 75.0% of the participants, and none of the patients reported severe reactions. CONCLUSION: Increased disease activity or relapse following vaccination with inactivated SARS-CoV-2 was rare in patients with inactive AOSD. Local and systemic adverse reactions were found to be mild and self-limiting. These safety profiles of inactivated SARS-CoV-2 vaccines in patients with AOSD may assist in eliminating vaccine hesitancy and increase the vaccination rate against SARS-CoV-2.
引用
- Hong X, Pan H, Su Y, et al. Inactivated SARS-CoV-2 vaccine does not increase the risk of relapse in patients with clinically inactive adult-onset Still's disease. Rheumatology (Oxford). 2023. PMID: 36282541. doi:10.1093/rheumatology/keac620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。